CBS 2019
CBSMD教育中心
中 文

推荐文献

Abstract

Recommended Article

Better Prognosis After Complete Revascularization Using Contemporary Coronary Stents in Patients With Chronic Kidney Disease Appropriate Use Criteria and Health Status Outcomes Following Chronic Total Occlusion Percutaneous Coronary Intervention: Insights From the OPEN-CTO Registry 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Mode of Death in Heart Failure With Preserved Ejection Fraction Association between urinary dickkopf-3, acute kidney injury, and subsequent loss of kidney function in patients undergoing cardiac surgery: an observational cohort study When high‐volume PCI operators in high‐volume hospitals move to lower volume hospitals—Do they still maintain high volume and quality of outcomes? Variation in Revascularization Practice and Outcomes in Asymptomatic Stable Ischemic Heart Disease 稳定性冠心病诊断与治疗指南

Original Research30 Jul 2018 [Epub ahead]

JOURNAL:Circulation. Article Link

The Astronaut Cardiovascular Health and Risk Modification (Astro-CHARM) Coronary Calcium Atherosclerotic Cardiovascular Disease Risk Calculator

A Khera , MJ Budoff , CJ O’Donnell et al. Keywords: coronary artery calcium; risk prediction

ABSTRACT


BACKGROUND - Coronary artery calcium (CAC) is a powerful novel risk indicator for atherosclerotic cardiovascular disease (ASCVD). Currently, there is no available ASCVD risk prediction tool that integrates traditional risk factors and CAC.


METHODS - To develop a CAC ASCVD risk tool for younger individuals in the general population, subjects aged 40-65 without prior CVD from three population-based cohorts were included. Cox proportional hazards models were developed incorporating age, sex, systolic blood pressure, total and HDL cholesterol, smoking, diabetes, hypertension treatment, family history of MI, high-sensitivity CRP (hs-CRP), and CAC scores (Astro-CHARM model) as dependent variables and ASCVD (non-fatal/fatal MI or stroke) as the outcome. Model performance was assessed internally, and validated externally in a fourth cohort.

RESULTS - The derivation study comprised 7382 individuals with mean age 51 years, 45% female, and 55% non-white. The median CAC was 0 (25-75th [0,9]) and 304 ASCVD events occurred in median 10.9 years of follow-up. The c-statistic was 0.784 for the risk factor model, and 0.817 for Astro-CHARM (p<0.0001). Compared with the risk factor model, the Astro-CHARM model resulted in integrated discrimination improvement (IDI=0.0252) as well as net reclassification improvement (NRI=0.121, p<0.0001). The Astro-CHARM model demonstrated good discrimination (c=0.78) and calibration (Nam-D’Agostino χ2:13.2, p=0.16) in the validation cohort (n=2057; 55 events). A mobile application and web-based tool were developed to facilitate clinical application of this tool ( www.AstroCHARM.org).

CONCLUSIONS - The Astro-CHARM tool is the first integrated ASCVD risk calculator to incorporate risk factors, including hs-CRP and family history, and CAC data. It improves risk prediction compared with traditional risk factor equations and could be useful in risk-based decision making for CV disease prevention in the middle-aged general population.